Human Combination Vaccines Market
Human Combination Vaccines Market, by Product Type (Inactivated Vaccine and Live Attenuated Vaccine), by Age Group (Children and Adults), by Combination Type (DTaP/IPV/Hep B, DTaP/Hib/IPV, MMR II, Hep B-Hib, and Others), by Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online Pharmacies) and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028.
Market Overview:
Human combination vaccines are vaccines that incorporate multiple antigens or immunogens to protect against multiple diseases in a single vaccine formulation. These vaccines are designed to simplify the vaccination process by reducing the number of injections required and improving patient compliance. Rather than administering separate vaccines for each disease, a combination vaccine combines antigens from different pathogens into a single vaccine product.
Competitive Landscape:
Major players operating in the global human combination vaccines market include NPS MedicineWise, Takeda Pharmaceutical Co. Ltd., CNBG, Emergent BioSolutions Inc, PaxVax Corporation, Biological, Influvac, AstraZeneca, Moderna, Serum Institute of India, Meiji Holdings Co. Ltd, Mass Biologics, Crunchbase Inc., Merck & Co., DAIICHI SANKYO COMPANY, LIMITED, Mitsubishi Tanabe Pharma Corp., CSL Ltd., GlaxoSmithKline plc, Cadila Healthcare Ltd., Pfizer Inc., and Sanofi.
Key Market Drivers:
Combination vaccines offer convenience by delivering protection against multiple diseases in a single administration. This simplifies vaccination schedules, reduces the number of healthcare visits, and improves patient compliance, especially in pediatric populations. This is expected to augment the growth of the global human combination vaccines market.
Human combination vaccines ensure broader protection against multiple diseases, including measles, mumps, rubella, diphtheria, pertussis, tetanus, and others. The comprehensive coverage provided by combination vaccines is a significant driver for their adoption, particularly in regions with high disease burdens. For instance, in May 2020, International AIDS Vaccine Initiative and Merck & Co., Inc. partnered in order to develop a novel vaccine candidate for COVID-19.
Combination vaccines offer cost advantages by reducing the number of individual vaccines required and associated healthcare visits. This is particularly beneficial in resource-constrained settings, where it streamlines immunization programs and optimizes healthcare resources.
Advances in vaccine technology have facilitated the development of safe and effective combination vaccines. The introduction of newer adjuvants, improved antigen selection, and formulation techniques have enhanced vaccine efficacy, which is estimated to enhance the growth of the global human combination vaccines market.
Covid-19 Impact Analysis:
The urgency of the COVID-19 pandemic has led to a surge in vaccine research and development efforts worldwide. This heightened focus on vaccines, including novel technologies such as mRNA vaccines, has accelerated advancements in the field and could have long-term positive implications for the global human combination vaccines market.For instance, in 2020, Sanofi Pasteur extended its partnership with Translate Bio, in order to create a novel mRNA vaccine candidate for COVID-19.
Key Takeaways:
· North America is expected to dominate the growth of the global human combination vaccines market, owing to robust healthcare infrastructure, high awareness about vaccination, and strong immunization programs. The region also benefits from extensive research and development activities in the field. For instance, in July 2020, Medicago and GSK partnered in order to introduce a COVID-19 adjuvant vaccine candidate.
· The Asia Pacific is estimated to witness high growth in the global human combination vaccines market, owing to a large population, high disease burden, and increasing investments in healthcare infrastructure. Government initiatives to improve vaccination coverage and growing awareness about immunization further fuel market growth. For instance, according to AmbitionBox, there are 175 major biotechnology companies in India.
